ArticleResearch square2026
Dual-functional Nanocarrier for Improved Immunochemotherapy of Acute Myeloid Leukemia.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Advances with the 7 + 3 regimen and liposomal CPX-351 have significantly improved the treatment of acute myeloid leukemia (AML); however, challenges like drug resistance and immune evasion persist. Despite the demonstrated potential of immunotherapy in treating several types of solid tumors, its impact on the treatment of AML remains limited. To address these challenges, we engineered an ultrasmall (~ 15 nm) cytarabine (AraC)-based polymeric micelle nanocarrier (PAraC) for efficient AML cell uptake and bone marrow niche targeting. scRNA-seq and real-world dataset analysis identified upregulated TLR7/8 in malignant AML cells, particularly after 7 + 3 treatment, supporting the inclusion of the TLR7/8 agonist R848 in our combination therapy. Our strategy integrates smart co-delivery of AraC, daunorubicin (Daun), and R848 using the PAraC platform. This triple nano-combination (PAraC/Daun/R848) demonstrated potent antitumor efficacy, outperforming CPX-351 and PAraC/Daun in multiple leukemia models, including murine and patient-derived xenografts (PDX) AML models and AraC-resistant acute lymphoblastic leukemia (ALL) model. Notably, PAraC/Daun/R848 reversed immunosuppressive phenotypes seen with CPX-351 or PAraC/Daun and induced robust leukemia cell maturation. With its modular design, efficient delivery, and remarkable preclinical performance, the PAraC platform holds immense promise for clinical translation, offering a new frontier for immunotherapeutic interventions in AML.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.